retatrutide turkey (LY3437943) | GCGR/GLP-1R/GIPR Agonist | CAS 2381089-83-2 Retatrutide 12mg Mimi Lost 37%

Lipid Panel Changes Retatrutide consistently improves lipid profiles: Triglycerides: Significant reductions, driven by reduced hepatic VLDL production and improved fat metabolism LDL cholesterol: Modest reductions observed HDL cholesterol: Tends to be preserved or mildly increased Non-HDL cholesterol: Meaningful improvements across studies These lipid changes are clinically relevant and contribute to the overall cardiovascular risk reduction profile

Tips for subcutaneous injection

Medication at room temperature (30-45 minutes out of fridge) Fresh, unused needle attached Injection site cleaned with alcohol and fully dried Site different from previous 4-6 injections No blood thinner or NSAID taken within 24 hours if possible Calm, relaxed mental state achieved Pressure applied for 60 seconds post injection planned Timing your injection around other medications can reduce bruising

doi: 10.1002/acr.20623 19 KwokLWTamLSZhuTLeungYYLiE

Semaglutide is a GLP-1 receptor agonist that works by increasing the activity of GLP-1, a neuroendocrine hormone produced in the intestines in response to food intake

It is estimated that approximately 1 in 4 people in the world have NAFLD